Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia

Jacques Louis Binet, Federico Caligaris-Cappio, Daniel Catovsky, Bruce Cheson, Tom Davis, Guillaume Dighiero, Hartmut Döhner, Michael Hallek, Peter Hillmen, Michael Keating, Emili Montserrat, Thomas J. Kipps, Kanti Rai

Research output: Contribution to journalArticlepeer-review


Recently, considerable progress has been made in the identification of molecular and cellular markers that may predict the tendency for disease progression in patients with chronic lymphocytic leukemia (CLL) or detect minimal residual disease after therapy. These developments have created uncertainty for clinicians who hope to incorporate the use of these markers and new disease-assessment tools into standard clinical practice. However, clinical trials are required to determine whether poor-prognosis leukemia-cell markers, such as expression of unmutated immunoglobulin genes or the zeta-associated protein of 70 kDa (ZAP-70), can be used as the basis for determining the time or type of therapy. Pending the outcome of such trials, treatment decisions outside the context of a clinical trial still should be based on guidelines established by the most recent National Cancer Institute-sponsored Working Group.

Original languageEnglish
Pages (from-to)859-861
Number of pages3
Issue number3
Publication statusPublished - Feb 1 2006

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia'. Together they form a unique fingerprint.

Cite this